Penn Medicine’s Cell Therapy and Transplant Program, part of the Division of Hematology and Oncology, stands out for its expertise in hematopoietic stem cell transplant and various cellular therapies.

Accredited by the Foundation for the Accreditation of Cell Therapy, it has conducted over 3,000 transplants over two decades, making it one of the nation’s largest programs. The program is also a leader in adoptive cell therapy for cancer, including the use of chimeric antigen receptor-modified T cells (CAR T). Research efforts focus on innovative cellular and vaccine immunotherapies, aiming to improve transplant outcomes and reduce disease relapse and toxicity.